Deerfield Management’s Relay Therapeutics RLAY Stock Holding History

Deerfield Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-46,702	Closed	-$304K	–	614
2024 Q2	$304K	Buy	+46,702	New	+$319K	0.01%	339

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Deerfield Management's RLAY Position: Q3 2024 in Review

Deerfield Management sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 46,702 shares — an estimated $304K sold.

Deerfield Management first reported a position in RLAY in Q2 2024 and held it in 1 quarter. The position peaked at $304K in Q2 2024. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

Deerfield Management reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
Deerfield Management sold 46,702 Relay Therapeutics shares in Q3 2024, an estimated $304K.
Deerfield Management first reported a position in Relay Therapeutics in Q2 2024 and held it in 1 quarter.
Deerfield Management's Relay Therapeutics position peaked at $304K in Q2 2024.
195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.